Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 59 Carcinoma, Hepatocellular 43 Colorectal Neoplasms 32 Stomach Neoplasms 28 Esophageal Squamous Cell Carcinoma 27 Squamous Cell Carcinoma of Head and Neck 20 Esophageal Neoplasms 14 Small Cell Lung Carcinoma 13 Neoplasm Metastasis 13 Lung Neoplasms 13 Head and Neck Neoplasms 12 Advanced Solid Tumor 12 Cholangiocarcinoma 11 Triple Negative Breast Neoplasms 10 Rectal Neoplasms 10 Nasopharyngeal Carcinoma 10 Melanoma 10 Uterine Cervical Neoplasms 9 Recurrence 9 Neoplasms 9 Colonic Neoplasms 9 Pancreatic Neoplasms 7 Urinary Bladder Neoplasms 6 Solid Tumor 6 Carcinoma, Transitional Cell 6 Breast Neoplasms 6 Sarcoma 5 Lymphoma, Extranodal NK-T-Cell 5 Lymphoma 5 Hodgkin Disease 5

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × tislelizumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡